{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T10:52:49Z","timestamp":1783075969520,"version":"3.54.6"},"reference-count":37,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2013,3,7]],"date-time":"2013-03-07T00:00:00Z","timestamp":1362614400000},"content-version":"vor","delay-in-days":1010,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2010,6]]},"abstract":"<jats:p>Clinical studies suggest that plasma levels of risperidone and its active moiety (risperidone + 9\u2010hydroxyrisperidone) correlate with adverse drug effects. The aim of this study is to evaluate the pharmacogenetic variability in the disposition of risperidone and the active moiety in healthy Chinese subjects. A 2\u2010mg single dose of risperidone is orally administered to 23 healthy Chinese subjects. The risperidone and 9\u2010hydroxyrisperidone serum concentrations are measured. The polymorphic alleles of CYP2D6*10, CYP3A5*3, MDR1 C1236T, G2677T\/A, and C3435T are determined in each subject. The mean maximum plasma concentration and area under the time\u2010concentration curve extrapolated to infinity for risperidone are significantly higher in subjects possessing the CYP2D6*10 allele than in those with the CYP2D6*1\/*1 and *1\/*10 genotype. For active moiety, the subjects who carry both homozygous CYP2D6*10 and homozygous CYP3A5*3 have 98% higher area under the time\u2010concentration curve extrapolated to infinity and 59% higher maximum plasma concentration compared with other CYP2D6 EM subjects. The MDR1 2677GA genotype may also play a role in risperidone pharmacokinetics. Further studies are needed to explore the impact of MDR1 2677GA and CYP3A5 polymorphisms on risperidone therapy.<\/jats:p>","DOI":"10.1177\/0091270009347867","type":"journal-article","created":{"date-parts":[[2010,3,24]],"date-time":"2010-03-24T02:41:16Z","timestamp":1269398476000},"page":"659-666","source":"Crossref","is-referenced-by-count":76,"title":["Effect of CYP2D6, CYP3A5, and MDR1 Genetic Polymorphisms on the Pharmacokinetics of Risperidone and Its Active Moiety"],"prefix":"10.1002","volume":"50","author":[{"given":"Qian","family":"Xiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing Li","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi Min","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,3,7]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002130000576"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002130051171"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/PL00005334"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/86882"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1124\/mol.62.1.162"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100052"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-3659(99)00034-6"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.97.7.3473"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2001.117412"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1301181"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145704004390"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2003.02061.x"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-973836"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e3181858ca9"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2002.127739"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2001.114164"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/48.10.1668"},{"key":"e_1_2_5_19_2","first-page":"1780","article-title":"Genetic polymorphisms of CYP2D6 in Chinese mainland","volume":"115","author":"Ji L","year":"2002","journal-title":"Chin Med J (Engl)"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2005.10.068"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2007.02912.x"},{"key":"e_1_2_5_22_2","first-page":"384","article-title":"Study on bioequivalence of risperidone tablets","volume":"41","author":"Jiao Z","year":"2006","journal-title":"Chin Pharm J"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2007.09.003"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/jso.20774"},{"key":"e_1_2_5_25_2","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0022-3565(24)29643-9","article-title":"Expression of P\u2010glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)\u20101 gene","volume":"297","author":"Tanabe M","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1159\/000156488"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270002239819"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02969428"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270007309888"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200208000-00014"},{"key":"e_1_2_5_31_2","article-title":"Clinical response to risperidone in relation to plasma drug concentrations in acutely exacerbated schizophrenic patients","author":"Yasui\u2010Furukori N","year":"2009","journal-title":"J Psychopharmacol"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v66n0103"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10038-006-0034-0"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(02)01680-6"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2007.01.028"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2005.03.009"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-7843.2008.00298.x"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.107.017434"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1177%2F0091270009347867","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/0091270009347867","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T17:33:27Z","timestamp":1739986407000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1177\/0091270009347867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["10.1177\/0091270009347867"],"URL":"https:\/\/doi.org\/10.1177\/0091270009347867","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}